Evidence map›Paper›PMID 40696842›Full record

ArticleScience progress

A stage IV high-grade serous ovarian cancer patient carrying

Baorang Zhu, Ying Liu, Jing Li, Wuwei Yang

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Baorang ZhuSenior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Ying LiuSenior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Jing LiSenior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Wuwei YangSenior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China.ORCID 0000-0002-6001-096X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer (OC), one of the most common gynecological cancers, is usually diagnosed at an advanced stage. High-grade serous ovarian cancer (HGSOC) is a histological subtype of OC that accounts for approximately 70% of all OC cases. erb-b2 receptor tyrosine kinase 2 (ERBB2) overexpression commonly occurs in HGSOC, accounting for 12.5% of stage III and IV HGSOCs. Currently, there is no established treatment strategy for OC patients with

Indexed as

AcrylamidesAminoquinolinesCystadenocarcinoma, SerousErb-b2 Receptor Tyrosine KinasesOvarian NeoplasmsFemaleGene AmplificationHumansMiddle AgedNeoplasm StagingAcrylamidesAminoquinolinesERBB2 protein, humanErb-b2 Receptor Tyrosine Kinasespyrotinibcase reportERBB2next-generation sequencingOvarian cancerpyrotinib

Identifiers

PMID40696842
PMCPMC12290328

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.